Polygenic embryo screening scrutiny

While this post focuses on ethics rather than validation performance, it defends embryo selection by arguing embryos lack moral personhood—an adjacent pillar to the policy debate over whether screening should be allowed or restricted.

The piece interrogates claims that embryo selection can raise IQ/height and examines a related claim—selecting embryos by ancestry proportion—directly engaging questions about performance claims, validation standards, and what clinics can responsibly market.

By spotlighting Orchid’s embryo screening for disease risk and the backlash labeling it 'eugenics,' the piece engages the broader contest over legitimacy of embryo polygenic risk scoring and public acceptance beyond technical performance claims.

The article labels embryo-testing firms as 'human culling agencies' and argues they don’t create healthier people, directly challenging performance claims and ethical framing central to the debate over embryo polygenic risk scoring and its regulation.

Orchid’s detailed public rebuttal on its Alzheimer’s predictor metrics and validation scope.

The article spotlights a new company (Herasight) claiming unusually strong within-family predictive performance for disease and IQ and directly addresses cross-ancestry accuracy gaps, which are central to ongoing disputes over validation standards, performance claims, and clinical use of embryo polygenic risk scoring.